Strong sales of anti-cancer drugs, AstraZeneca's Q2 revenue increased by 12% year-on-year, exceeding expectations | Financial Report Insights

British pharmaceutical giant AstraZeneca delivered a second-quarter financial report that exceeded market expectations, thanks to strong sales performance of its cancer drugs.

According to the financial report released by AstraZeneca on Tuesday, the company's revenue for the second quarter reached $14.46 billion, a year-on-year increase of 12%, surpassing analysts' expectations of $14.15 billion. Core earnings per share reached $2.17, a year-on-year increase of 10%, slightly exceeding market expectations.

Despite the impressive performance, AstraZeneca maintained its full-year performance expectations, stating that pricing pressures and global trade risks remain challenges. At the same time, the company has announced plans to invest $50 billion in the United States by 2030 to expand production and R&D capabilities in response to potential drug tariff threats from the Trump administration.

Cancer Drugs Continue to Drive Revenue Growth

As the main driver of AstraZeneca's performance growth, the company's oncology drug portfolio has shown particularly strong results. The company's cancer drug product line not only solidified its market position in oncology but also provided a solid foundation for overall revenue growth.

AstraZeneca CEO Pascal Soriot stated in a statement, "Our strong momentum in revenue growth has continued into the first half of this year, and our diverse product pipeline has delivered outstanding performance."

In addition to cancer drugs, AstraZeneca's sales of cardiovascular and kidney disease medications also performed strongly, collectively supporting the company's performance in the second quarter.

Clear U.S. Market Expansion Strategy

In the face of potential tariffs on imported drugs from the Trump administration, AstraZeneca announced an ambitious U.S. market expansion plan last week.

The company has committed to investing $50 billion in the United States by 2030 to expand production and R&D capabilities, demonstrating its determination to produce drugs locally.

This move makes AstraZeneca the latest pharmaceutical company to respond to the threat of Trump tariffs by increasing investment in the U.S. Through this strategy, AstraZeneca hopes not only to alleviate potential trade pressures but also to achieve its goal of reaching $80 billion in annual revenue by 2030 through expanding its U.S. business and enriching its drug pipeline.

Key Progress in R&D Pipeline

As the largest publicly traded company in the UK by market capitalization, AstraZeneca's progress in its R&D pipeline is crucial for its future performance. The company expects to launch 20 new drugs, which will be key factors in achieving its revenue target for 2030.

Notably, the late-stage clinical trial results of the potential blockbuster drug Datroway for lung cancer treatment will be announced later this year, which is significant for the drug's market prospects and the company's stock performance.

Despite AstraZeneca's recent positive results in the development of other drugs, including a hypertension medication and a treatment for myasthenia gravis (an autoimmune disease), its stock performance this year has still lagged behind its domestic competitor GSK